HPM Executive

Sydney based Executive Search & Selection practice. Our core business is securing Senior Executive talent for clients in the Health & Life Sciences sector

[HPM Executive @HPMExecutive]

@JaneCaro @authorVTaylor Much much bigger!

[HPM Executive @HPMExecutive]

If #ASXBio markets are close to the bottom of the cycle, why doesn't the sector consolidate or liquidate the stragglers? hint: it's people https://t.co/bX8d5bjyXw

[HPM Executive @HPMExecutive]

Clickbait or a matter worthy of serious debate?
Is all the hoop-la regarding company Values just a load of hot air? https://t.co/9vRg023h62

[ANDHealth @ANDHealthAU]

The support of gender diversity across the digital health sector is one of our core values. It's great to see that our FY2023 Industry Sentiment Survey report shows an upward trend in gender diversity compared to FY2022 – let’s celebrate that 🎉 Read more:https://t.co/Zdsk6L91Dg

[Craig Cooper @craigcooperrrrr]

Me, Zoom briefing my staff over the weekend on a slightly important milestone in the company $CDX.

[HPM Executive @HPMExecutive]

Will capital markets start to move again for #ASXBio?
Orbital raises $270 million in biotech’s largest Series A round this year https://t.co/QMZVR5bD2X via @BioPharmaDive

[HPM Executive @HPMExecutive]

Tough times for Biotech workers in the USA. Are #ASXBiotech cutting as hard? I think not. Biotechs see 'staggering' 87% rise in layoffs during Q1, on pace to overtake 2022 https://t.co/CfyGkNgVqF

[HPM Executive @HPMExecutive]

Fantastic news from @ANDHealthAU and @brandoncapital offering access up to $5m in non-dilutive funding over a 5-year period to support the translation and commercial development of #biomedical and #digitalhealth technologies.

[ANDHealth @ANDHealthAU]

We are delighted to announce that ANDHealth, in partnership with Brandon BioCatalyst, has been selected by the Medical Research Future Fund to deliver the $50m BioMedTech Incubator Program (#BMTI).

Learn more: https://t.co/d1ZgtCs0fO

[HPM Executive @HPMExecutive]

Prof. Sandra Cooper is Australia's leading authority in the clinical interpretation of genetic Splicing Variants. This @NatureGenet publication outlines her team's latest innovation in the field.

[CMRI @CMRI_AUS]

Congratulations to Professor Sandra Cooper, Adjunct Research Scientist at CMRI, for developing a world-first database which could change the way genetic disease is diagnosed.

https://t.co/RaB4LAQsiK

[FierceBiotech @FierceBiotech]

Gilead landed its Kite unit at Arcellx to work on a multiple myeloma cell therapy, a deal worth $225 million upfront.
https://t.co/4rgQhyCbpy

[HPM Executive @HPMExecutive]

Do yourselves a favour, Twitter. Follow this guy.

[Dr. Glaucomflecken @DGlaucomflecken]

The farmer pain scale

[HPM Executive @HPMExecutive]

@ANDHealthAU - investing in international partnerships that directly impact commercial outcomes for Australian #DigitalHealth innovations

[ANDHealth @ANDHealthAU]

Yesterday we ran our first Ireland-Australia Digital Health Exchange in Dublin 🇮🇪

@Bron_LeGrice shared an overview of the Australian #digitalhealth sector and three of our ANDHealth+ 2022 cohort companies showcased Australian innovation in #digitalhealth.

[HPM Executive @HPMExecutive]

Australian research that improves classification of splicing variants is the most read @GIMJournal during 2022! #variantclassification #geneticdiagnosis #splicingvariant

[Genetics in Medicine @GIMJournal]

#EditorsChoice
"Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants" https://t.co/nCMo2RTF3O by Adam M. Bournazos et al. #geneticdiagnosis #variantclassification

[HPM Executive @HPMExecutive]

Uni Melbourne investing cash and credibility into the Valley of Death. As the self-styled leading university in Australia, will USyd respond in kind, or go one up?
https://t.co/03TtPQAkPW

[Adam Feuerstein ✡️ @adamfeuerstein]

Dear biotech management teams —

I understand you’re stressed about your plunging stock price, but the solution is NOT to rush out tiny amounts of ambiguous data. You look desperate, not confident.

[HPM Executive @HPMExecutive]

Have there simply been too many Biotech IPO's? #ASXBio
https://t.co/udyv6xo6Yw

[HPM Executive @HPMExecutive]

To what extent do the personal actions of employees become the domain of their employer - and their wrath?
I Quit So I Could Be Free. https://t.co/Ud9gU86pGR

[Dr. Glaucomflecken @DGlaucomflecken]

It’s not about the money

[ANDHealth @ANDHealthAU]

Join global industry thought leader, executive and investor Lisa Suennen @VentureValkyrie and ANDHealth CEO @Bron_LeGrice as they explore the cultural collisions that can occur when #health meets #tech and how companies might navigate them. Book now: https://t.co/0EjLTJSHiY

[HPM Executive @HPMExecutive]

Bio/tech startups & early stage ventures must confront multiple barriers - most of which they cannot control. Attracting and retaining the best talent need not be one of them. https://t.co/YZoezCdqTd